G
Giulia Pasello
Researcher at University of Padua
Publications - 158
Citations - 2672
Giulia Pasello is an academic researcher from University of Padua. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 19, co-authored 113 publications receiving 1597 citations.
Papers
More filters
Journal ArticleDOI
Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer
Alessandra Buja,Giulia Pasello,Marco Schiavon,Giuseppe De Luca,Michele Rivera,Claudia Cozzolino,Anna de Polo,Manuela Scioni,Alberto Bortolami,Vincenzo Baldo,Pierfranco Conte +10 more
TL;DR: The purpose of this study was to provide policymakers with an estimate of the cost‐effectiveness of durvalumab in the treatment of non‐small cell lung cancer (NSCLC).
Journal ArticleDOI
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Elisabetta Zulato,Paola Del Bianco,Giorgia Nardo,Ilaria Attili,Alberto Pavan,Andrea Boscolo Bragadin,Ludovica Marra,Giulia Pasello,Matteo Fassan,Fiorella Calabrese,Valentina Guarneri,Pierfranco Conte,Stefano Indraccolo,Laura Bonanno +13 more
TL;DR: In this article , a longitudinal liquid biopsy was used to characterize patients experiencing hyperprogression (HPD) and early death (ED) by quantifying cell-free DNA (cfDNA) and variant allele fraction (VAF).
Journal ArticleDOI
Skip pattern approach toward the early access of innovative anticancer drugs.
Giovanni Apolone,Andrea Ardizzoni,Andrea Biondi,A. Bortolami,Claudia Cardone,Chiara Maura Ciniselli,Pierfranco Conte,C. Crippa,F. de Braud,Matteo Duca,Stefania Gori,G. Gritti,Alessandro Inno,R. Luksch,F. Lussana,Michele Maio,Giulia Pasello,F. Perrone,Alessandro Rambaldi,Giulio Rossi,Diego Signorelli,G. Soverini,M.M. Valente,Paolo Verderio,Giuliano Buzzetti +24 more
TL;DR: In this article, the authors proposed a reliable methodological pathway for the assessment of clinical value of new therapeutic innovative options, to objectively identify drugs which deserve early access (EA) priority for solid and possibly in other cancer scenarios, such as the hematological ones.
Journal ArticleDOI
Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
Giulia Pasello,Martina Lorenzi,G. Pretelli,Giovanni Maria Comacchio,Federica Pezzuto,Marco Schiavon,Alessandra Buja,Stefano Frega,Laura Bonanno,Valentina Guarneri,Fiorella Calabrese,Federico Rea +11 more
TL;DR: Reflex EGFR testing in all early-stage NSCLC at diagnosis or after surgery appears to be a valid tool to give patients the chance to benefit from targeted adjuvant treatment.
Journal ArticleDOI
E18Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study
Stefano Frega,Marianna Macerelli,A. Del Conte,L. Bonanno,Michele Bartoletti,Valentina Polo,G. Zago,Alessandro Follador,Ilaria Attili,Alberto Pavan,Loredana Urso,Smm Basso,Gianpiero Fasola,Pierfranco Conte,Giulia Pasello +14 more